Valuation dashboard for Labcorp Holdings Inc. (LH) with P/E 29.03, P/B 3.24, EV/EBITDA 16.4 and dividend yield 0.81%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
What would it be worth at its usual multiples?
Versus its usual multiples: expensive · Current P/E 29.0× · Multiples range: $205.28 · $374.11.
At the decade median (16.8×) $205 (-42 %); at its sector median (30.7×) $374 (+6 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
Analysis Summary
Labcorp Holdings Inc. reported revenue of $13.95B in the most recent fiscal year, growing at a 5-year CAGR of -0.0%. Net income reached $876.5M, with a -10.8% 5-year CAGR.
Trailing-twelve-month margins: gross margin 27.9%, operating margin 11.1%, net margin 6.9%.
At $353.92 (closing price, November 3, 2026), LH trades at a P/E of 29.03 and an ROE of 11.54%. Market capitalisation stands at $28.7B, placing it among large-cap names.
Balance sheet quality for LH: debt-to-equity ratio of 0.77, current ratio of 1.41 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 29.03 |
| Price / Book | 3.24 |
| EV / EBITDA | 16.4 |
| Dividend Yield | 0.81% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LH | Labcorp Holdings Inc. | $28.7B | 29.03 | 3.24 | 11.5% |
| NTRA | Natera, Inc. | $56.0B | 30.57 | -11.7% | |
| GH | Guardant Health, Inc. | $23.5B | 211.5% | ||
| GRAL | GRAIL Inc. | $6.2B | 2.36 | -15.9% | |
| TMO | Thermo Fisher Scientific Inc. | $258.7B | 36.83 | 4.72 | 13.3% |
| DGX | Quest Diagnostics Incorporated | $27.3B | 24.61 | 3.56 | 15.2% |
| QGEN | Qiagen N.V. | $10.4B | 25.84 | 3.09 | 11.6% |
Price
| Price | $353.92 (closing price, November 3, 2026) |
| Market Cap | $28.7B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 11.54% |
| Return on Invested Capital | 7.88% |
| Return on Assets | 5.31% |
| Gross Margin | 27.95% |
| Operating Margin | 11.12% |
| Net Margin | 6.88% |
Related companies: NTRA · GH · GRAL · TMO · DGX · QGEN
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of LH: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks